Sign In
Buy BDSX
$16.10
+0.660 (+4.27%)
At Close: Jun 03, 2026
BDSX Stock Rises After Publication of Study Data for Nodify CDT Test
08:31am, Wednesday, 08'th Jan 2025
Biodesix announces positive study data for its Nodify CDT blood-based lung nodule test published in CHEST Pulmonary Journal.
Biodesix Announces Publication of a New Nodify CDT® Clinical Validation Study
06:00am, Tuesday, 07'th Jan 2025
Analysis of 447 patients receiving the Nodify CDT blood-based lung nodule test published in CHEST Pulmonary Journal reaffirms test performance Analysis of 447 patients receiving the Nodify CDT blood-b
Biodesix (BDSX) Loses -22.98% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:35am, Wednesday, 20'th Nov 2024
The heavy selling pressure might have exhausted for Biodesix (BDSX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts i
Biodesix, Inc. (BDSX) Q3 2024 Earnings Call Transcript
03:29pm, Friday, 01'st Nov 2024
Biodesix, Inc. (NASDAQ:BDSX ) Q3 2024 Earnings Conference Call November 1, 2024 8:30 AM ET Company Participants Chris Brinzey - Investor Relations Scott Hutton - Chief Executive Officer Robin Harper C
Biodesix, Inc. (BDSX) Reports Q3 Loss, Misses Revenue Estimates
08:16am, Friday, 01'st Nov 2024
Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.12 per share a year ago.
Biodesix Announces Third Quarter 2024 Results and Highlights
06:00am, Friday, 01'st Nov 2024
Q3 2024 revenue grew 35% over Q3 2023 to $18.2 million; Q3 2024 gross profit margin of 77.0%, up from 76.1% in Q3 2023; Q3 2024 Net loss improved by 6% compared to Q3 2023; Conference Call and Webcast
Biodesix to Participate in Three Investor Conferences in November
06:00am, Tuesday, 29'th Oct 2024
LOUISVILLE, Colo., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive O
Biodesix to Report Third Quarter 2024 Financial Results on November 1, 2024
06:00am, Friday, 18'th Oct 2024
LOUISVILLE, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the t
Biodesix Announces New Data Presentation at CHEST 2024 Annual Meeting and the Launch of a Complementary Clinical Study
06:00am, Monday, 07'th Oct 2024
LOUISVILLE, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data will be presented at the CHEST Ann
Biodesix, Inc. (BDSX) Q2 2024 Earnings Call Transcript
08:52pm, Wednesday, 07'th Aug 2024
Biodesix, Inc. (NASDAQ:BDSX ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Chris Brinzey - IR Scott Hutton - CEO Robin Harper Cowie - CFO Conference Call Participant
Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates
07:05pm, Wednesday, 07'th Aug 2024
Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.17 per share a year ago.
Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E
09:06am, Thursday, 27'th Jun 2024
Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include CLEAR Secure (YOU), Applied DNA Sciences (APDN), Phreesia (PHR), Vigil Neuroscience (VIGL) and Biodesix
Biodesix Named to Inc. Magazine's 2024 “Best Workplaces”
08:13am, Tuesday, 18'th Jun 2024
LOUISVILLE, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, is honored to announce it has been named to Inc. Magazine's Best Wor
Biodesix to Participate in Two Investor Conferences in June
06:00am, Tuesday, 28'th May 2024
LOUISVILLE, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Exe
Biodesix to Present New Data on the Nodify XL2® Test at ATS 2024 Annual Meeting
06:00am, Tuesday, 21'st May 2024
LOUISVILLE, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced that new data will be present
